New hope for thalassemia patients: drug may cut blood transfusions

NCT ID NCT07215975

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. Researchers will follow 200 participants in the Middle East to track real-world results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia beta-thalassemia major thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Prince Muhammad bin Nasser Hospital

    NOT_YET_RECRUITING

    Jizan, Saudi Arabia

  • Sultan Qaboos University Hospital

    RECRUITING

    Seeb, Muḩāfaz̧at Masqaţ, 123, Oman

    Contact